MASTER CLINICAL SERVICES AGREEMENT between TARGACEPT, INC. and FORENAP PHARMA EURL Page 1 / 33Master Clinical Services Agreement • November 9th, 2007 • Targacept Inc • Pharmaceutical preparations
FORENAP PHARMA EURL, having its registered offices at 27 rue du 4ème RSM – B.P. 27, F-68250 ROUFFACH, France, represented by Rémy LUTHRINGER, Ph.D., CEO, hereinafter referred to as “FORENAP”
PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN SMITHKLINE BEECHAM CORPORATION, D/B/A GLAXOSMITHKLINE AND GLAXO GROUP LIMITED AND TARGACEPT, INC.Product Development And • November 9th, 2007 • Targacept Inc • Pharmaceutical preparations • Delaware
This PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into and made effective as of the 27th day of July 2007 (the “Effective Date”) by and between Targacept, Inc., a Delaware corporation having its principal place of business at 200 East First Street, Winston-Salem, North Carolina 27101 (“Targacept”), on the one hand, and SmithKline Beecham Corporation, doing business as GlaxoSmithKline, a Pennsylvania corporation having a principal place of business at One Franklin Plaza, Philadelphia, PA 19101 (“SB”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GGL”), on the other hand. SB and GGL are referred to herein collectively as “GSK.” Targacept and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
STOCK PURCHASE AGREEMENT BY AND BETWEEN TARGACEPT, INC. AND GLAXO GROUP LIMITED DATED AS OF JULY 27, 2007Stock Purchase Agreement • November 9th, 2007 • Targacept Inc • Pharmaceutical preparations • North Carolina
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of July 27, 2007, by and between Targacept, Inc., a Delaware corporation (the “Company”), and Glaxo Group Limited, a company organized under the laws of England (“GSK”).
